Demographic and clinical characteristics of initial patients receiving amyloid-targeting treatments in the United States after regulatory approval.

ABSTRACT:

Introduction

Three treatments for Alzheimer's disease have been approved in the United States. Data are lacking on the characteristics of the initial treatment recipients.

Methods

We identified treatment recipients in the full Medicare fee-for-service data for 2021 to 2023. We compared their age, sex, race/ethnicity, dual eligibility, comorbidities, and median household income and educational attainment in their residence's ZIP Code Tabulation Area (ZCTA) to those of the overall Medicare population aged 65+.

Results

Treated patients were more likely to be non-Hispanic White (89% vs 82%) and less likely to be dually eligible (1% vs 8.8%). Average median household income ($97,136 vs $84,449) and proportion of residents with at least a bachelor's degree (41% vs 31%) were

SUBMITTER: Mattke S 

PROVIDER: S-EPMC11881614 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature